Our Commitment to Cancer Research
By Yuri Rukazenkov, MD, Medical Science Director, AstraZeneca
This week, I will join a global team of AstraZeneca employees in Texas for the annual San Antonio Breast Cancer Symposium (SABCS). This annual meeting is a chance for the scientific, academic, clinician, and patient communities to interact and exchange research and information that helps us better understand and develop treatment options for breast cancer.
At SABCS, AstraZeneca will be presenting six studies around breast cancer treatment research, including updated results from a previously reported phase III study.
But each year in San Antonio, and each day at AstraZeneca, the patients, advocates, and researchers that we meet serve as reminders to how much more we can and must do to meet the needs of the breast cancer community.
While advances in treatment and detection have been made over the years, breast cancer remains the leading cause of cancer death in women around the world and the second leading cause of cancer deaths among US women.
That’s why AstraZeneca is committed to continuing our more than 30-year history of researching, discovering, and developing medicines to fight cancer. We want to provide more resources and more medical research for people with metastatic breast cancer, a form of advanced breast cancer also referred to as stage IV breast cancer that is diagnosed when cancer has spread from the breast to other parts of the body and is generally not curable.
Recently, we launched FALCON, a new global study for some patients with advanced or metastatic breast cancer. And while our current focus is on researching treatments for metastatic breast cancer, the area where we believe patient need is currently the greatest, AstraZeneca has a long heritage in breast cancer and is committed to leading the way in developing and optimizing breast cancer therapies for all patient groups.
For more information about all of our ongoing clinical trials in the Unites States, visit www.clinicaltrials.gov